Principal Financial Group
UBX

Principal Financial Group’s Unity Biotechnology UBX Stock Holding History

Principal Financial Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,051
Closed -$32K – 2636
2021
Q3 		$32K Sell
1,051
-171
-14% -$6.03K ﹤0.01% 2557
2021
Q2 		$57K Buy
1,222
+66
+6% +$3.18K ﹤0.01% 2565
2021
Q1 		$69K Buy
1,156
+82
+8% +$5.59K ﹤0.01% 2441
2020
Q4 		$56K Buy
+1,074
New +$51.8K ﹤0.01% 2388

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Principal Financial Group's UBX Position: Q4 2021 in Review

Principal Financial Group sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 1,051 shares — an estimated $32K sold.

Principal Financial Group first reported a position in UBX in Q4 2020 and held it in 4 quarters. The position peaked at $69K in Q1 2021. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • Principal Financial Group reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 1,051 Unity Biotechnology shares in Q4 2021, an estimated $32K.
  • Principal Financial Group first reported a position in Unity Biotechnology in Q4 2020 and held it in 4 quarters.
  • Principal Financial Group's Unity Biotechnology position peaked at $69K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.